Esmaeili Farzad, Vahabi Seyed Mohammad, Abdoli Mohammadsadegh, Fazeli Patrick, Ghandi Narges, Seddigh Leila, Aryanian Zeinab, Etesami Ifa
School of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran.
Department of Dermatology Razi Hospital, Tehran University of Medical Sciences Tehran Iran.
Skin Health Dis. 2024 Aug 19;4(5):e441. doi: 10.1002/ski2.441. eCollection 2024 Oct.
Alopecia areata (AA) is an autoimmune disease causing chronic non-scarring hair loss. Different therapeutic regimens have been suggested for AA, which depend on patients' age, scalp involvement extent and duration. Topical immunotherapy with diphenylcyclopropenone (DPCP) is one of the treatment options for these patients.
We aimed to investigate the response to DPCP in paediatric AA patients.
This retrospective study included 97 paediatric AA patients followed in the DPCP clinic from March 2016 to March 2021 at a referral dermatology hospital.
In a cohort of 97 paediatric patients with AA under treatment with DPCP, with a mean age of 11.10 ± 0.9, 53.6% of the patients were male. Patchy alopecia was the most prevalent type (45.4%). After 6 months of DPCP treatment, 51.5% showed no response, while 3.1% achieved complete response. At the 12-month evaluation, among the 68 patients who continued treatment, complete response was observed in 8.8%. A significant positive correlation was found between alopecia type, specifically patchy, and treatment response ( = 0.031). Additionally, treatment duration emerged as a significant predictor of positive response at both six (OR 1.450, = 0.026) and 12 months (OR 1.310, = 0.043). A higher initial Severity of Alopecia Tool score was inversely correlated with treatment response (Spearman's rho -0.14, = 0.002), indicating that initial disease severity may predict treatment efficacy.
One year after the onset of DPCP in paediatric AA patients, the complete response and any hair regrowth rates were 8.8% and 61.8%, respectively. The milder initial disease severity and longer duration of treatment resulted in a better response.
斑秃（AA）是一种导致慢性非瘢痕性脱发的自身免疫性疾病。针对斑秃，已提出了不同的治疗方案，这些方案取决于患者的年龄、头皮受累程度和病程。用二苯环丙烯酮（DPCP）进行局部免疫疗法是这些患者的治疗选择之一。
我们旨在研究儿童斑秃患者对DPCP的反应。
这项回顾性研究纳入了2016年3月至2021年3月在一家转诊皮肤科医院的DPCP门诊随访的97例儿童斑秃患者。
在一组接受DPCP治疗的97例儿童斑秃患者中，平均年龄为11.10±0.9岁，53.6%的患者为男性。斑片状脱发是最常见的类型（45.4%）。DPCP治疗6个月后，51.5%的患者无反应，而3.1%的患者达到完全缓解。在12个月评估时，在继续治疗的68例患者中，8.8%观察到完全缓解。发现脱发类型，特别是斑片状，与治疗反应之间存在显著正相关（P = 0.031）。此外，治疗持续时间在6个月（OR 1.450，P = 0.026）和12个月（OR 1.310，P = 0.043）时均成为阳性反应的显著预测因素。较高的初始脱发严重程度工具评分与治疗反应呈负相关（斯皮尔曼相关系数 -0.14，P = 0.002），表明初始疾病严重程度可能预测治疗效果。
儿童斑秃患者开始使用DPCP一年后，完全缓解率和任何毛发再生率分别为8.8%和61.8%。初始疾病严重程度较轻和治疗持续时间较长导致反应较好。
